WO1997047317A1 - Combination of a somatostatin analogue and a rapamycin - Google Patents
Combination of a somatostatin analogue and a rapamycin Download PDFInfo
- Publication number
- WO1997047317A1 WO1997047317A1 PCT/EP1997/003036 EP9703036W WO9747317A1 WO 1997047317 A1 WO1997047317 A1 WO 1997047317A1 EP 9703036 W EP9703036 W EP 9703036W WO 9747317 A1 WO9747317 A1 WO 9747317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- residue
- formula
- somatostatin
- Prior art date
Links
- 0 Cc(cc1)ccc1O* Chemical compound Cc(cc1)ccc1O* 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a pharmaceutical combination and its use in the treatment of disorders associated with excess benign and malignant cell proliferation, e.g tumors or intimal cell proliferation.
- a pharmaceutical combination comp ⁇ sing a compound of the somatostatin class, and a rapamycin macrolide.
- the somatostatin class is a known class of small peptides comprising the naturally occurring somatostatin- 14 and analogues having somatostatin related activity, e.g. as disclosed by A.S. Dutta in Small Peptides, Vol.19, Elsevier (1993).
- somatostatin analogue as used herein is meant any straight-chain or cyclic polypeptide having a structure based on that of the naturally occurring somatostatin- 14 wherein one or more ammo acid units have been omitted and/or replaced by one or more other ammo rad ⁇ cal(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups.
- the term covers all modified derivatives of the native somatostatin- 14 which exhibit a somatostatin related activity, e.g.
- somatostatin receptor hSST-1, hSST-2, hSST-3, hSST-4 or hSST-5
- hSST-1, hSST-2, hSST-2, hSST-3, hSST-4 or hSST-5 somatostatin receptor
- Cyclic, bridge cyclic and straight-chain somatostatin analogues or derivatives are known and have been described together with processes for their production e.g. in US Patent Specifications 4,310,518 and 4,235,886, in European Patent Specifications EP- A- 1295; 23,192; 29,310; 29,579; 30,920; 31,303; 63,308; 70,021 ; 83,305; 215,171; 203,031; 214,872; 143,307; 298,732; 277,419; 389,180; 395,417; 450,480A2; in Belgian Patent Specification BE-A-900,089; and in WO 91/09056; WO 97/01579; WO 97/14715, the contents thereof, in particular with respect to the compounds, being incorporated herein by reference.
- Preferred somatostatin analogues are e. g. compounds of formula I
- A is C,. ⁇ 2 alkyl, C 7 . 10 phenylalkyl or a group of formula RCO-, whereby i) R is hydrogen, C, .,, alkyl, phenyl or C 7 ., 0 phenylalkyl, or ii) RCO- is
- A' is hydrogen or C,. 3 alkyl
- Y, and Y 2 represent together a direct bond or each of Y, and Y 2 is hydrogen
- B is -Phe- optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C,. 3 alkyl and /or C,. 3 alkoxy (including pentafluoroalanine), naphthylalanine or pyridylalanine,
- C is (L)-Trp- or (D)-Trp- optionally ⁇ -N-methylated and optionally benzene- ring-substituted by halogen, NO 2 , NH 2 , OH, C, .3 alkyl and/or C,. 3 alkoxy,
- D is Lys, 4-aminocyclohexylAla or 4-aminocyclohexylGly
- E is Thr, Ser, Val, Tyr, He, Leu or an aminobutyric or aminoisobutyric acid residue
- G is a group of formula
- R 7 is hydrogen or C,. 3 alkyl
- R, 0 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester, e.g. formyl, C 2. , 2 alkylcarbonyl, benzoyl, R u is hydrogen, C,. 3 alkyl, phenyl or C 7 . 10 phenyl-alkyl, R l2 is hydrogen, C,.
- a physiologically acceptable, physiologically hydrolysable ester e.g. formyl, C 2. , 2 alkylcarbonyl, benzoyl
- R u is hydrogen, C,. 3 alkyl, phenyl or C 7 . 10 phenyl-alkyl
- R l2 is hydrogen, C,.
- R 13 is CH 2 OH, -(CH 2 ) 2 -OH, -(CH 2 ) 3 -OH, -CH(CH 3 )OH, isobutyl, butyl, benzyl, naphthyl-methyl or indol-3-yl-methyl, and
- X is a group of formula
- R 7 and R ]0 have the meanings given above,
- R l4 is hydrogen or C, 3 alkyl
- R 15 is hydrogen, C,. 3 alkyl, phenyl or C 7 . 10 phenylalkyl, and
- R, 6 is hydrogen or hydroxy
- R ⁇ : is -CH(R 13 )-Xj then R, is hydrogen or methyl
- residues B, D and E have the L-configuration, and the residues in the 2- and 7-pos ⁇ t ⁇ on each independently have the (L)- or (D)- configuration,
- a preferred compound of formula I is octreotide.
- Acid addition salts may be formed with e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates.
- Complexes are e.g. formed from compounds of the invention on addition of inorganic substances, e.g. inorganic salts or hydroxides such as Ca- and Zn-salts, and/or an addition of polymeric organic substances.
- somatostatin analogues suitable for use in accordance with the present invention are: cyclo [-Asn-Phe-Phe-DT ⁇ -Lys-Thr-Phe-Gaba-], cyclo(Asu-Lys-Asn-Phe-Phe-T ⁇ -Lys-Thr-Tyr-Thr-Ser), and
- the somatostatin component of the combination is a somatostatin analogue comprising the amino acid sequence of formula (II) -(D/L)T ⁇ -Lys-X 2 -X 3 - (II)
- X 2 is a radical of formula (a) or (b)
- R is optionally substituted phenyl
- R 2 is -Z,-CH 2 -R réelle -CH 2 -CO-O-CH 2 -R disregard
- Z is O or S
- X 3 is an ⁇ -ammo acid having an aromatic residue on the C ⁇ side chain, or an amino acid unit selected from Dab, Dpr, Dpm, H ⁇ s,(Bzl)HyP ⁇ o, thienyl- Ala, cyclohexyl-Ala and t.-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys 9 of the native somatostatin- 14.
- Such somatostatin analogues are e.g. disclosed in WO/ 97/01579, the contents thereof, m particular with respect to the specifically exemplified compounds, being inco ⁇ orated herein by reference.
- the sequence of formula LI as defined above corresponds to the residues at positions 8 through 1 1 of the somatostatin- 14.
- the somatostatin analogue as disclosed above comprises a hexapeptide unit, the residues at positions 3 through 6 of said hexapeptide unit comprising the sequence of formula II.
- the hexapeptide unit is cyclic, e.g. having a direct peptide linkage between the ⁇ -carbonyl group of the residue at position 6 and the ⁇ -amino group of the residue at position 1.
- T ⁇ may have the D- or L-configuration, preferably the D-configuration.
- X 2 is preferably a residue of formula (a) or (b), R 2 being preferably -Z,-CH 2 -R, or
- X 3 comprises an aromatic residue on the C ⁇ side chain
- it may suitably be a natural or unnatural ⁇ -amino acid, e.g. Phe, Tyr, T ⁇ , Nal, Pal, benzothienyl-Ala, Tic and thyronin, preferably Phe or Nal, more preferably Phe.
- X 3 is preferably an ⁇ -amino acid bearing an aromatic residue on the C ⁇ side chain.
- R is substituted phenyl
- it may suitably be substituted by halogen, methyl, ethyl, methoxy or ethoxy e.g. in ortho and/or para. More preferably R, is unsubstituted phenyl.
- Z is preferably O.
- Representative somatostatin analogues comprising a residue of formula II are e.g compounds of formula (III)
- X 2 and X 3 are as defined above,
- A is a divalent residue selected from Pro
- R 3 is NR g R 0 -C 2 . 6 alkylene, guanidino-C 2 6 alkylene or C 2 . 6 alkylene-COOH
- R 3a is H, C M alkyl or has independently one of the significances given for R 3
- R 3b is H or C M alkyl
- R a is OH or NR 5 R 6
- R b is -(CH 2 ) 1 3 - or -CH(CH 3 )-
- R 4 is H or CH 3
- R 4a is optionally ring-substituted benzyl
- each of R 5 and R 6 independently is H, C M alkyl, o>amino-C M alkylene, ⁇ -hydroxy-C M alkylene or acyl
- R 5l is a direct bond or C,.
- each of R g and R 9 independently is H, C,. 4 alkyl, ⁇ -hydroxy-C w alkylene, acyl or CH 2 OH-(CHOH) c -CH 2 - wherein c is 0, 1, 2, 3 or 4, or R 8 and R 9 form together with the nitrogen atom to which they are attached a heterocyclic group which may comprise a further heteroatom, and R, 7 is optionally ring-substituted benzyl, -(CH 2 ),. 3 -OH, CH 3 -CH(OH)- or -(CH 2 ),. 5 -NR 5 R 6 , and ZZ a is a natural or unnatural ⁇ -amino acid unit.
- ZZ a may have the D- or L-configuration.
- ZZ a is a natural or unnatural ⁇ -amino acid unit, it may suitably be e.g. Thr, Ser, Ala, Val, He, Leu, Nle, His, Arg, Lys, Nal, Pal, Tyr, T ⁇ , optionally ⁇ ng-substituted Phe or N ⁇ -benzyl-Gly.
- the benzene ring thereof may be substituted by e.g. NH 2 , NO 2 , CH 3 , OCH 3 or halogen, preferably in para position
- ZZ a is Phe, the benzene ⁇ ng thereof is preferably unsubstituted
- any substituent present on the proline ring e.g R 3 -NH-CO-O- etc., is preferably in position 4.
- Such substituted proline residue may exist in the cis form, e.g
- the present invention covers each geometric isomer individually as well as mixtures thereof.
- A is (NR 8 R 9 -C 2 . 6 alkylene-NH-CO-O)Pro- where NR 8 R 9 forms a heterocyclic group, such group may be aromatic or saturated and may comprise one nitrogen or one nitrogen and a second heteroatom selected from nitrogen and oxygen
- the heterocyclic group is e.g. py ⁇ dyl or mo ⁇ hohno.
- C 2 . 6 Alkylene in this residue is preferably -CH 2 -CH 2 -.
- Any acyl as R 5 , R 6 , R g and R 9 in A may be e.g. R lg CO- wherein R lg is H, C M alkyl, C 2u) alkenyl, C 3 . 6 cycloalkyl or benzyl, preferably methyl or ethyl.
- R 4a or R ]7 in A is ⁇ ng-substituted benzyl, the benzene ring may be substituted as indicated above for ZZ_.
- a preferred group of compounds of formula LTJ are such wherein A, is free of a lateral -NH-CO-O- moiety.
- a further group of preferred compounds of formula LTJ are such wherein A, comprises a basic lateral radical, e.g. a R 3 -NH-CO-O- or R 5 -N-R 5a - moiety
- a still further group of preferred compounds of formula III are such wherein the N- terminal amino acid comprises a substituted Pro, particularly 4-subst ⁇ tuted Pro, e.g. compounds of formula III wherein A, is 4-subst ⁇ tuted Pro.
- A is 4-(R 3 -NH-CO-O)Pro.
- somatostatin analogues comprising a residue of formula II include e.g. cyclo[4-(NH 2 -C 2 H 4 -NH-CO-0-)Pro-Phe-DT ⁇ -Lys-Ser(Benzyl)-Phe]
- macrocyclic lactone for example a compound having a 12-membered or larger lactone ⁇ ng
- lactone macrohdes i.e. macrocyclic compounds having a lactam (amide) bond in the macrocycle in addition to a lactone (ester) bond
- Rapamycin is an immunosuppressive lactam macrolide that is produced by Streptomyces hygroscopicus. and having the structure depicted in Formula A
- rapamycin derivatives are 40-0-substituted derivatives of rapamycin having the structure of Formula IV:
- X 4 is (H,H) or O;
- Y 3 is (H,OH) or O;
- R 20 and R 21 are independently selected from H, alkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxycarbonylalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, dialkyl-dioxolanylalkyl, di(alkoxycarbonyl)- triazolyl-alkyl and hydroxy alkoxy-alkyl; wherein "alk-" or “alkyl” refers to C, .6 alkyl, branched or linear, preferably C,. 3 alkyl,; "aryl” is phenyl or tolyl; and acyl is a radical
- R 22 is methyl or R 22 and R 20 together form C 2 . 6 alkyl; provided that R 20 and R 21 are not both H; and hydroxyalkoxyalkyl is other than hydroxy alkoxy methyl .
- a preferred compound is e.g. 40-O-(2-hydroxy)ethyl-rapamycin (referred thereafter as Compound B).
- rapamycin derivatives are e.g. those disclosed in WO 96/41807, the contents thereof, in particular with respect to the specifically exemplified compounds of formula I disclosed therein, being inco ⁇ orated herein by reference.
- Particularly preferred are 32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-40-O-(2-hydroxyethyl)-rapamycin,
- rapamycin derivatives are known, e.g. carboxylic acid esters such as disclosed in WO 92/05179, amide esters such as disclosed in US 5 1 18 677, carbamates such as described in US 5 1 18 678, fluorinated esters such as disclosed in US 5 100 883, acetals, e.g. in US 5 151 413, silyl ethers, e.g. in US 5 120 842, arylsulfonates and sulfamates, e.g. in US 5 177 203, derivatives wherein the methoxy group at the position 16 is replaced with alkynyloxy, e.g. in WO 95/16691 and further derivatives such as disclosed in WO 93/1 1 130, WO 94/02136, WO 94/02385 and WO 95/14023, all inco ⁇ orated herein by reference.
- carboxylic acid esters such as disclosed in WO 92/05179
- amide esters
- Rapamycin and above mentioned derivatives have been shown to have potent immunosuppressant properties. Rapamycin has also been shown to inhibit smooth muscle cell proliferation and to inhibit cancer growth.
- Somatostatin analogues e.g. octreotide, vapreotide and lanreotide, have been disclosed i. a. to inhibit growth hormone secretion and to have an inhibiting effect on malignant tumor growth, e.g. in breast cancer.
- Octreotide and lanreotide have also been disclosed to inhibit smooth muscle cell proliferation.
- a method for preventing or treating cell hype ⁇ roliferation in a subject in need of such treatment which comprises administering to such subject a synergistically effective amount of a compound of the somatostatin class in free form or in pharmaceutically acceptable salt form, and a rapamycin macrolide.
- kits or package for the treatment or prevention of cell hype ⁇ roliferation including a pharmaceutical composition comprising a compound of the somatostatin class in free form or in pharmaceutically acceptable salt form, and a pharmaceutical composition comprising a rapamycin macrolide.
- the kit or package may also contain instructions to use the pharmaceutical compositions in accordance with the present invention.
- the combination of a compound of the somatostatin class and a rapamycin macrolide is indicated for the prevention or treatment of malignant tumor growth, e.g. breast, lung, GEP tumors, pituitary adenomas, lymphomas, etc., for the prevention or treatment of proliferative vascular diseases, e.g. biologically or mechanically induced vascular injury causing intimal thickening, e.g.
- malignant tumor growth e.g. breast, lung, GEP tumors, pituitary adenomas, lymphomas, etc.
- proliferative vascular diseases e.g. biologically or mechanically induced vascular injury causing intimal thickening, e.g.
- transplant vasculopathies for example chronic rejection of various tissues and organs such as heart, kidney, pancreas, lung, liver, bowel, trachea and combined heart-lung.
- the combination is particularly indicated for preventing intimal smooth muscle cell hype ⁇ iasia, restenosis and vascular occlusion in a mammal.
- AR42J cell cultures are propagated in DMEM supplemented with 10 % fetal calf serum (FCS) at 5 % CO 2 . Cells are grown in the absence of antibiotics or antifungal agents. Subconfluent AR42J cells growing in DMEM and supplemented with 10 % FCS are trypsinized, diluted in DMEM + 2.5 % FCS and seeded in uncoated 96-well plates (5'000 to 10O00 cells per well in 180 ⁇ l). After a 48-hr incubation period (Day O), the number of cells in a separate control plate is determined both by counting cells in a Coulter counter and by the sulforhodamine B (SRB) staining assay.
- FCS fetal calf serum
- the cells are then exposed either to the somatostatin analogue alone, e.g. octreotide, or to rapamycin or a derivative thereof alone or to a combination of the somatostatin analogue and rapamycin or its derivative up to 5 days at various concentrations.
- Total drug exposure lasts for up to 5 days following the first addition and SRB analysis as described above is performed e.g. on day 2 and day 5.
- the AR42J (AR4-2J) rat pancreatic tumor cell line is derived from an azaserine- induced exocrine pancreatic tumor (Jessop and Hay, 1980). It was obtained from ATCC. Cultures are propagated m DMEM supplemented with 10% fetal calf serum (FCS) at 5% CO : . Cells are grown in the absence of antibiotics or antifungal agents. Female nude mice (nu/nu Balbc-A from Iffa Credo, Lyon, France) weighing 19-22 g, are kept in groups of 5 animals in macrolon cages (type ITJ, 16 x 22 x 1 1 cm).
- the cages are placed in ventilated cabinets (Iffa Credo) that are maintained at 24 ⁇ 1 ° C
- the animals have free access to drinking water and a pathogen-free rodent diet (Diet A, Kliba, Basel, Switzerland)
- a pathogen-free rodent diet Diet A, Kliba, Basel, Switzerland
- AR42J cells are trypsinized and lOxlO 6 tumor cells (in 0 2 ml) are injected subcutaneously (s.c.) into both flanks of nude mice.
- s.c. subcutaneously
- animals are randomized into control and treatment groups
- Control animals receive placebo. Animals are treated as indicated below for 3 weeks with single agents or the drug combination.
- the somatostatin analogue is given as a single injection of a slow release form at 30 mg/kg s.c.
- Patients are included who have breast cancer as evidenced by histological biopsy (glandular analysis - EOA) They present a metastatic illness and/or loco-regional localisation which is measurable and evaluable. If desired, patients may be included who are resistant to other treatment to conventional therapy such as surgery, radiotherapy, other chemotherapy and/or hormone therapy.
- the patients present at least one target, on X-ray analysis, which is measurable or evaluable such as a pnmitive metastatic tumour which is cutaneous or sub-cutaneous. It may be gangliar or visceral
- the patients Preferably have lesions which have progressed within the month preceding the trial and have an estimated survival time of at least 3 months
- the rapamycin macrolide e.g rapamycin or compound B is administered orally
- the treatment is for at least 3 months or until complete remission.
- the response may be followed by conventional methodology, e.g. according to IUCC response criteria, e.g. progression, stabilization, partial or complete remission.
- the somatostatin analogue e.g. octreotide
- parenterally e.g subcutaneous, particularly in a continuous subcutaneous way by means of a portable sy ⁇ nge pump (infusion pump).
- the somatostatin analogue and the rapamycin macrolide are preferably administered in the form of a pharmaceutical composition.
- Rapamycin and its derivatives e.g. Compound B
- the somatostatin analogue may also be administered in a slow release form, e.g. as disclosed in UK Patent Specification 2,265,31 IB.
- the administration of each component of the combination may take place either separately, simultaneously or sequentially, e.g. rapamycin or Compound B may be administered at first followed later, e.g. 8 to 24 hours later, by the somatostatin analogue.
- Rapamycin or its derivatives may conveniently be administered at doses which are in the range used in immunosuppressive applications such as prevention and treatment of graft vs. host disease, transplant rejection or autoimmune diseases e.g. at a daily dosage from about 0.5 to 500 mg as a single dose or in divided doses. Such doses may also be given intermittently, for example, every other day or every third day.
- the somatostatin analogue may be administered, e.g. subcutaneously, in a dosage range of about 100 ⁇ g to 10 mg per day as a single dose or in divided doses.
- octreotide may be administered at a dose of from 0.2 mg to 10 mg twice or three times daily.
- such formulation may comprise the somatostatin peptide in a concentration from 2.0 to 10% by weight.
- the release period of such a formulation may be from 1 week to about 2 months.
- the combination of the somatostatin analogue with rapamycin or its derivative allows to maximize the antiproliferative effect.
- Biodegradable sustained release formulation Octreotide Acetate 4.65 % (by weight)
- Rapamvcin (or derivative thereof) formulation e.g. capsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50120398A JP3784418B2 (en) | 1996-06-11 | 1997-06-11 | Combination of somatostatin analog and rapamycin |
DE69719320T DE69719320T2 (en) | 1996-06-11 | 1997-06-11 | COMBINATION OF A SOMATOSTATIN ANALOG AND A RAPAMYCIN |
DK97928175T DK0896544T3 (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
US09/194,957 US6362164B1 (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
CA002249439A CA2249439C (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
EP97928175A EP0896544B1 (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
AT97928175T ATE233098T1 (en) | 1996-06-11 | 1997-06-11 | COMBINATION OF A SOMATOSTATIN ANALOG AND A RAPAMYCIN |
AU32572/97A AU3257297A (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9612171.0 | 1996-06-11 | ||
GBGB9612171.0A GB9612171D0 (en) | 1996-06-11 | 1996-06-11 | Organic compounds |
GB9619310.7 | 1996-09-16 | ||
GBGB9619310.7A GB9619310D0 (en) | 1996-09-16 | 1996-09-16 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047317A1 true WO1997047317A1 (en) | 1997-12-18 |
Family
ID=26309485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/003036 WO1997047317A1 (en) | 1996-06-11 | 1997-06-11 | Combination of a somatostatin analogue and a rapamycin |
Country Status (10)
Country | Link |
---|---|
US (1) | US6362164B1 (en) |
EP (1) | EP0896544B1 (en) |
JP (1) | JP3784418B2 (en) |
AT (1) | ATE233098T1 (en) |
AU (1) | AU3257297A (en) |
CA (1) | CA2249439C (en) |
DE (1) | DE69719320T2 (en) |
DK (1) | DK0896544T3 (en) |
ES (1) | ES2193379T3 (en) |
WO (1) | WO1997047317A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001043776A1 (en) * | 1999-12-17 | 2001-06-21 | Lipotec, S.A. | Pharmaceutical formulation for intravenous or intramuscular octreotide administration |
WO2002066019A2 (en) * | 2001-02-19 | 2002-08-29 | Novartis Ag | Cancer treatment |
US6613874B1 (en) | 1999-03-29 | 2003-09-02 | The Procter & Gamble Company | Melanocortin receptor ligands |
EP1787658A1 (en) | 2005-11-10 | 2007-05-23 | South Shore Properties Inc. | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
WO2007057457A2 (en) * | 2005-11-21 | 2007-05-24 | Novartis Ag | Neuroendocrine tumor treatment using mtor inhibitors |
US7741362B2 (en) | 2003-10-06 | 2010-06-22 | Siegfried Wurster | Somatostatin receptor 1 and/or 4 selective agonists and antagonists |
AU2007201060B2 (en) * | 2001-02-19 | 2011-07-07 | Novartis Ag | Cancer treatment |
WO2012013190A2 (en) | 2010-07-29 | 2012-02-02 | Linak A/S | Lifting column preferably for height-adjustable tables |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
AU2011226833B2 (en) * | 2001-02-19 | 2014-05-22 | Novartis Ag | Cancer treatment |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
US10016392B2 (en) | 2011-07-14 | 2018-07-10 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
WO2021065985A1 (en) | 2019-09-30 | 2021-04-08 | 株式会社理研バイオ-アルツハイマー病の発症前診断と予防的治療のために | Somatostatin receptor |
US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298299A3 (en) * | 2000-01-14 | 2012-02-29 | The Trustees Of The University Of Pennsylvania | O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
EP1522311A1 (en) * | 2003-10-10 | 2005-04-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women |
AU2005238493A1 (en) * | 2004-04-27 | 2005-11-10 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
JP2009254391A (en) * | 2006-07-18 | 2009-11-05 | Tetsuhiko Katsumata | Holder and accessory for ball marker of golf |
US20130011488A1 (en) * | 2011-07-07 | 2013-01-10 | Nezami Md Mohammad | Systems, Methods, and Formulations for Treating Cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2239178A (en) * | 1987-07-10 | 1991-06-26 | Sandoz Ltd | Somatostatin analogues for the treatment of breast cancer |
WO1993011130A1 (en) * | 1991-12-03 | 1993-06-10 | Smithkline Beecham Plc | Rapamycin derivative and its medicinal use |
-
1997
- 1997-06-11 EP EP97928175A patent/EP0896544B1/en not_active Expired - Lifetime
- 1997-06-11 AU AU32572/97A patent/AU3257297A/en not_active Abandoned
- 1997-06-11 JP JP50120398A patent/JP3784418B2/en not_active Expired - Lifetime
- 1997-06-11 WO PCT/EP1997/003036 patent/WO1997047317A1/en active IP Right Grant
- 1997-06-11 ES ES97928175T patent/ES2193379T3/en not_active Expired - Lifetime
- 1997-06-11 US US09/194,957 patent/US6362164B1/en not_active Expired - Lifetime
- 1997-06-11 DK DK97928175T patent/DK0896544T3/en active
- 1997-06-11 CA CA002249439A patent/CA2249439C/en not_active Expired - Lifetime
- 1997-06-11 DE DE69719320T patent/DE69719320T2/en not_active Expired - Lifetime
- 1997-06-11 AT AT97928175T patent/ATE233098T1/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2239178A (en) * | 1987-07-10 | 1991-06-26 | Sandoz Ltd | Somatostatin analogues for the treatment of breast cancer |
WO1993011130A1 (en) * | 1991-12-03 | 1993-06-10 | Smithkline Beecham Plc | Rapamycin derivative and its medicinal use |
Non-Patent Citations (1)
Title |
---|
SHI E.A.: "Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro", CANCER RESEARCH, vol. 55, 1 May 1995 (1995-05-01), pages 1982 - 1988, XP002040888 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951916B2 (en) | 1999-03-29 | 2005-10-04 | The Procter & Gamble Company | Melanocortin receptor ligands |
US6613874B1 (en) | 1999-03-29 | 2003-09-02 | The Procter & Gamble Company | Melanocortin receptor ligands |
ES2167189A1 (en) * | 1999-12-17 | 2002-05-01 | Lipotec Sa | Pharmaceutical formulation for intravenous or intramuscular octreotide administration |
WO2001043776A1 (en) * | 1999-12-17 | 2001-06-21 | Lipotec, S.A. | Pharmaceutical formulation for intravenous or intramuscular octreotide administration |
JP4912551B2 (en) * | 1999-12-17 | 2012-04-11 | リポテック,エス.アー. | Stable formulations for intravenous and intramuscular administration of active peptide compounds |
US6521599B2 (en) | 1999-12-17 | 2003-02-18 | Lipotec, S.A. | Stable pharmaceutical formulation for intravenous or intramuscular administration of active peptide compounds |
JP2003517024A (en) * | 1999-12-17 | 2003-05-20 | リポテック,エス.アー. | Stable formulations for intravenous and intramuscular administration of active peptide compounds |
EP2764865A3 (en) * | 2001-02-19 | 2014-10-01 | Novartis AG | Cancer treatment |
EP3351246A1 (en) * | 2001-02-19 | 2018-07-25 | Novartis AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
CN1296043C (en) * | 2001-02-19 | 2007-01-24 | 诺瓦提斯公司 | Cancer treatment |
CZ309247B6 (en) * | 2001-02-19 | 2022-06-22 | Novartis Ag | 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour |
EP2269603B1 (en) | 2001-02-19 | 2015-05-20 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with exemestane |
CZ309178B6 (en) * | 2001-02-19 | 2022-04-20 | Novartis Pharma Ag | 40-O- (2-hydroxyethyl) rapamycin for use in therapy |
EP3345602B1 (en) | 2001-02-19 | 2022-04-06 | Novartis Pharma AG | Rapamycin derivative for treating solid tumours |
AU2019222912B2 (en) * | 2001-02-19 | 2020-09-03 | Novartis Ag | Cancer treatment |
EP2269603A1 (en) * | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2269604A1 (en) * | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
AU2007201060B2 (en) * | 2001-02-19 | 2011-07-07 | Novartis Ag | Cancer treatment |
AU2017276287B2 (en) * | 2001-02-19 | 2019-10-17 | Novartis Ag | Cancer treatment |
EP3342411B1 (en) | 2001-02-19 | 2019-08-21 | Novartis Pharma AG | Rapamycin derivative for treating pancreas cancer |
WO2002066019A3 (en) * | 2001-02-19 | 2002-10-24 | Novartis Ag | Cancer treatment |
EP3351246B1 (en) | 2001-02-19 | 2019-05-22 | Novartis AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
CZ303611B6 (en) * | 2001-02-19 | 2013-01-09 | Novartis Ag | Pharmaceutical compositions containing rapamycin derivative and intended for treating solid tumors |
NO333105B1 (en) * | 2001-02-19 | 2013-03-04 | Novartis Ag | Use of 40-O- (2-hydroxyethyl) -rapamycin in the preparation of a pharmaceutical composition for use in cancer treatment |
US8410131B2 (en) | 2001-02-19 | 2013-04-02 | Novartis Pharmaceuticals Corporation | Cancer treatment |
CZ307637B6 (en) * | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O- (2-Hydroxyethyl) rapamycin as the only active ingredient in the treatment |
US8436010B2 (en) | 2001-02-19 | 2013-05-07 | Novartis Pharmaceuticals Corporation | Treatment of solid tumors with rapamycin derivatives |
AU2011226833B2 (en) * | 2001-02-19 | 2014-05-22 | Novartis Ag | Cancer treatment |
US8778962B2 (en) | 2001-02-19 | 2014-07-15 | Novartis Pharmaceuticals Corporation | Treatment of solid tumors with rapamycin derivatives |
EP2762140A1 (en) * | 2001-02-19 | 2014-08-06 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
NO335134B1 (en) * | 2001-02-19 | 2014-09-22 | Novartis Ag | Pharmaceutical combination comprising 40-O- (2-hydroxyethyl) -rapamycin and the exemestane co-agent and use thereof |
EP2783686A1 (en) * | 2001-02-19 | 2014-10-01 | Novartis AG | Combination of a rapamycin derivative and letrozole for treating breast cancer |
WO2002066019A2 (en) * | 2001-02-19 | 2002-08-29 | Novartis Ag | Cancer treatment |
CN104083365A (en) * | 2001-02-19 | 2014-10-08 | 诺华股份有限公司 | Cancer treatment |
US8877771B2 (en) | 2001-02-19 | 2014-11-04 | Novartis Pharmaceuticals Corporation | Treatment of solid tumors with rapamycin derivatives |
EP3143995B1 (en) | 2001-02-19 | 2018-12-05 | Novartis Ag | Rapamycin derivative for the treatment of lung cancer |
EP3406249A1 (en) * | 2001-02-19 | 2018-11-28 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor |
AU2014202334B2 (en) * | 2001-02-19 | 2016-05-12 | Novartis Ag | Cancer treatment |
EP2269604B1 (en) | 2001-02-19 | 2016-07-27 | Novartis AG | Treatment of solid kidney tumours with a rapamycin derivative |
EP2762140B1 (en) | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
EP3143995A1 (en) * | 2001-02-19 | 2017-03-22 | Novartis Ag | A rapamycin derivative for treating lung cancer |
EP2783686B1 (en) | 2001-02-19 | 2017-06-21 | Novartis AG | Combination of a rapamycin derivative and letrozole for treating breast cancer |
IL259724A (en) * | 2001-02-19 | 2018-08-30 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin and pharmaceutical compositions comprising same for use in the treatment of solid excretory system tumors |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
AU2007201060C1 (en) * | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
AU2014202334C1 (en) * | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
NO20190290A1 (en) * | 2001-02-19 | 2003-10-17 | Novartis Ag | Cancer treatment |
EP3342411A1 (en) * | 2001-02-19 | 2018-07-04 | Novartis AG | Rapamycin derivative for treating pancreas cancer |
EP3345602A1 (en) * | 2001-02-19 | 2018-07-11 | Novartis AG | Rapamycin derivative for treating advanced solid tumours |
US7741362B2 (en) | 2003-10-06 | 2010-06-22 | Siegfried Wurster | Somatostatin receptor 1 and/or 4 selective agonists and antagonists |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
EP1787658A1 (en) | 2005-11-10 | 2007-05-23 | South Shore Properties Inc. | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
NO341023B1 (en) * | 2005-11-21 | 2017-08-07 | Novartis Ag | Use of 40-O- (2-hydroxyethyl) -rapamycin in carcinoid tumor treatment |
WO2007057457A2 (en) * | 2005-11-21 | 2007-05-24 | Novartis Ag | Neuroendocrine tumor treatment using mtor inhibitors |
EP2275103A3 (en) * | 2005-11-21 | 2011-10-12 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
EP2022498A3 (en) * | 2005-11-21 | 2012-08-15 | Novartis AG | Neuroendocrine tumour treatment |
AU2006314444C1 (en) * | 2005-11-21 | 2018-01-04 | Novartis Ag | Neuroendocrine tumor treatment using mTOR inhibitors |
US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
AU2006314444B2 (en) * | 2005-11-21 | 2010-08-26 | Novartis Ag | Neuroendocrine tumor treatment using mTOR inhibitors |
WO2007057457A3 (en) * | 2005-11-21 | 2008-01-10 | Novartis Ag | Neuroendocrine tumor treatment using mtor inhibitors |
WO2012013190A2 (en) | 2010-07-29 | 2012-02-02 | Linak A/S | Lifting column preferably for height-adjustable tables |
US11890269B2 (en) | 2011-07-14 | 2024-02-06 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
US10966957B2 (en) | 2011-07-14 | 2021-04-06 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
US10016392B2 (en) | 2011-07-14 | 2018-07-10 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2021065985A1 (en) | 2019-09-30 | 2021-04-08 | 株式会社理研バイオ-アルツハイマー病の発症前診断と予防的治療のために | Somatostatin receptor |
Also Published As
Publication number | Publication date |
---|---|
JP2000514415A (en) | 2000-10-31 |
ATE233098T1 (en) | 2003-03-15 |
JP3784418B2 (en) | 2006-06-14 |
AU3257297A (en) | 1998-01-07 |
ES2193379T3 (en) | 2003-11-01 |
DK0896544T3 (en) | 2003-05-05 |
EP0896544A1 (en) | 1999-02-17 |
CA2249439A1 (en) | 1997-12-18 |
US6362164B1 (en) | 2002-03-26 |
CA2249439C (en) | 2009-09-08 |
DE69719320T2 (en) | 2003-12-11 |
EP0896544B1 (en) | 2003-02-26 |
DE69719320D1 (en) | 2003-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0896544B1 (en) | Combination of a somatostatin analogue and a rapamycin | |
EP0944396B1 (en) | Compositions and methods for enhancing intestinal function | |
US9303067B2 (en) | Sustained release formulation comprising a somatostatin analogue | |
CA1328402C (en) | Somatostatins | |
PT1615640E (en) | Antineoplastic combinations | |
JP2809707B2 (en) | Arthritis treatment | |
US20100317583A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) | |
JP4672257B2 (en) | Compositions containing epothilone and their use for the treatment of carcinoid syndrome | |
EP1648934B1 (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
Jaquet | Evidence for dopamine agonists in the treatment of acromegaly | |
JP3022915B2 (en) | Cancer metastasis inhibitor | |
EP1632244A1 (en) | Preventives or remedies for hepatopathy | |
GB2239178A (en) | Somatostatin analogues for the treatment of breast cancer | |
JP2764041B6 (en) | Improvements on somatostatins | |
WO2002009739A1 (en) | Treatment of ocular disorders with somatostatin analogues | |
HU206271B (en) | Process for producing pharmaceutical compositions against breast cancer, comprising somatostatin analog as active ingredient | |
Haddock et al. | The effect of the somatostatin analogue SMS 201-995 on experimental pancreatic carcinogenesis in the Syrian golden hamster | |
EP2114439A1 (en) | Use of somatostatin analogs in cluster headache |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997928175 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2249439 Country of ref document: CA Ref country code: CA Ref document number: 2249439 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09194957 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997928175 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997928175 Country of ref document: EP |